AGN Allergan plc

158.25
+1.91  (+1%)
Previous Close 156.34
Open 157.03
Price To Book 0.87
Market Cap 51,911,177,149
Shares 328,032,715
Volume 3,024,148
Short Ratio 1.18
Av. Daily Volume 5,468,817

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 trial to be completed 2H 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 ongoing.
Brazikumab
Crohn's disease
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
Phase 3 data released January 24, 2019 - primary endpoint met in rheumatoid arthritis trial. Non-Hodgkin’s lymphoma data due 3Q 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 data due in 2020.
ATOGEPANT
Chronic migraine
Phase 3 trials did not meet primary endpoints - March 6, 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
BLA filing due 2H 2019.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
FDA Approval announced May 28, 2019.
Cariprazine
Bipolar I Depression
NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
UBROGEPANT
Migraine
Phase 2/3 trial ongoing.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020.
Bimatoprost
Open-angle glaucoma or ocular hypertension
FDA Approval announced March 18, 2019.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI) - pediatric
PDUFA date 4Q 2019.
Botox
Lower limb spasticity
FDA Approval announced June 21, 2019.
Botox
Upper limb spasticity
Phase 2 top-line data due 2H 2019.
AGN-241751
Major Depressive Disorder (MDD)
Phase 3 top-line data due 2020.
Presbysol
Presbyopia
Phase 2 monotherapy interim analysis 2H 2019.
RAPASTINEL
Depression